JPMorgan Chase & Co. Has $4.66 Million Stake in Autolus Therapeutics plc (NASDAQ:AUTL)

JPMorgan Chase & Co. grew its holdings in Autolus Therapeutics plc (NASDAQ:AUTL) by 145.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,284,708 shares of the company’s stock after purchasing an additional 761,008 shares during the quarter. JPMorgan Chase & Co. owned about 0.48% of Autolus Therapeutics worth $4,663,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the business. Wellington Management Group LLP raised its holdings in shares of Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after buying an additional 6,330,392 shares during the last quarter. State Street Corp increased its position in Autolus Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 606,544 shares of the company’s stock valued at $2,202,000 after acquiring an additional 10,401 shares in the last quarter. HighVista Strategies LLC raised its stake in shares of Autolus Therapeutics by 2.7% in the third quarter. HighVista Strategies LLC now owns 533,024 shares of the company’s stock worth $1,935,000 after acquiring an additional 14,204 shares during the last quarter. Erste Asset Management GmbH acquired a new position in shares of Autolus Therapeutics during the third quarter worth approximately $708,000. Finally, Bellevue Group AG grew its stake in shares of Autolus Therapeutics by 27.7% during the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock valued at $151,000 after purchasing an additional 9,000 shares during the last quarter. Institutional investors own 72.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a report on Friday, November 15th. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the company from $7.00 to $7.60 in a research note on Monday, November 18th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, January 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Price Performance

AUTL opened at $2.22 on Friday. The firm has a 50 day simple moving average of $2.70 and a 200 day simple moving average of $3.56. Autolus Therapeutics plc has a fifty-two week low of $2.07 and a fifty-two week high of $7.37. The company has a market cap of $590.72 million, a price-to-earnings ratio of -1.83 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter in the prior year, the company posted ($0.26) EPS. As a group, analysts expect that Autolus Therapeutics plc will post -0.94 EPS for the current year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.